BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2018 6:15:25 AM | Browse: 1142 | Download: 1750
 |
Received |
|
2018-05-02 00:44 |
|
Peer-Review Started |
|
2018-05-03 02:24 |
|
First Decision by Editorial Office Director |
|
2018-05-16 18:22 |
|
Return for Revision |
|
2018-05-22 00:36 |
|
Revised |
|
2018-06-14 10:21 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-06-28 10:18 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-06-28 23:37 |
|
Articles in Press |
|
2018-06-28 23:37 |
|
Edit the Manuscript by Language Editor |
|
2018-07-12 21:15 |
|
Typeset the Manuscript |
|
2018-09-06 04:10 |
|
Publish the Manuscript Online |
|
2018-09-07 06:15 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Alberto Mella, Ester Gallo, Maria Messina, Cristiana Caorsi, Antonio Amoroso, Paolo Gontero, Aldo Verri, Francesca Maletta, Antonella Barreca, Fabrizio Fop and Luigi Biancone |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Luigi Biancone, MD, PhD, Professor, Renal Transplantation Center "A. Vercellone", Division of Nephrology Dialysis and Transplantation, Department of Medical Sciences, Città della Salute e della Scienza Hospital and University of Turin, Corso Bramante 88, Turin 10126, Italy. luigi.biancone@unito.it |
| Key Words |
Chronic-active antibody-mediated rejection; Kidney transplantation; Donor-specific antibody; Rituximab |
| Core Tip |
Chronic-active antibody-mediated rejection (cAMR) is one of the major causes of poor long-term outcome in kidney transplantation, with no effective treatments currently available. We retrospectively compared 21 kidney transplant recipients with a diagnosis of cAMR, nine treated with plasmapheresis, intravenous immunoglobulins and rituximab vs 12 patients not treated with antibody-targeted therapies. Our data showed improvement in microvascular inflammation in post-therapy protocol biopsies without differences in functional outcomes at 24 mo, suggesting the lack of a prompt and marked effect of this therapeutic protocol. Further studies are required to improve the management and long-term results of this severe condition. |
| Publish Date |
2018-09-07 06:15 |
| Citation |
Mella A, Gallo E, Messina M, Caorsi C, Amoroso A, Gontero P, Verri A, Maletta F, Barreca A, Fop F, Biancone L. Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results. World J Transplant 2018; 8(5): 178-187 |
| URL |
http://www.wjgnet.com/2220-3230/full/v8/i5/178.htm |
| DOI |
http://dx.doi.org/10.5500/wjt.v8.i5.178 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
